News & Media
Newsroom
XCOPRI® (cenobamate tablets) CV Receives FDA Approval for Alternate Methods of Administration That Include Crushed Tablet in Liquid Suspension Taken Orally or Through a Nasogastric Tube
4.11.2024
Full Release
SK Life Science Announces Data Presentations for XCOPRI® (cenobamate tablets) CV at the 2024 American Academy of Neurology Annual Meeting
4.9.2024
Full Release
SK Life Science Appoints Dr. Sunita Misra, MD, PhD, as Vice President of Global Clinical Development and Acting Chief Medical Officer
4.8.2024
Full Release
Welcome to the news and information center for SK Life Science, Inc.
To learn more about SK Life Science, please download our corporate fact sheet
For more information about epilepsy, please download this infographic
For more information about Lennox-Gastaut syndrome, please download this fact sheet
SK Life Science at a Glance
Headquarters Location: Paramus, NJ
R&D Begins: 1993
Parent Company: SK Life Science is a subsidiary of SK Biopharmaceuticals, CO., LTD, and both are a part of SK Group
Number of Employees: 200+ Employees
Disease Category Focus: CNS Disorders and Oncology
Pipeline: 8 compounds under clinical development